Related Experiment Video

Updated: Aug 12, 2026

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix
09:11

Cell-based Therapy for Heart Failure in Rat: Double Thoracotomy for Myocardial Infarction and Epicardial Implantation of Cells and Biomatrix

Published on: September 22, 2014

Beta-blocker therapy for heart failure

M L Slatton1, E J Eichhorn

  • 1Cardiac Catheterization Laboratory (IIIA2), University of Texas Southwestern, Dallas, USA.

Current Opinion in Cardiology
|May 1, 1996
PubMed

Insights

New treatments for heart failure are needed. Beta-adrenergic blockade may reverse harmful effects of high adrenergic tone in heart failure patients, offering a potential new therapy.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Congestive heart failure (CHF) persists as a significant health issue with high mortality, despite current treatments like diuretics, digoxin, and angiotensin-converting enzyme inhibitors.
  • Elevated adrenergic tone in CHF patients is detrimental, contributing to disease progression and poor outcomes.
  • Existing therapies are insufficient, highlighting the urgent need for novel therapeutic strategies for heart failure management.

Purpose of the Study:

  • To review recent advancements in understanding the pathophysiology of congestive heart failure.
  • To examine current data on the efficacy of beta-blocking agents in treating heart failure.
  • To explore the role of beta-adrenergic blockade in mitigating the adverse effects of high adrenergic tone in CHF.

Main Methods:

  • Review of evidence from basic research, animal studies, and clinical human trials.
  • Analysis of recent data concerning the treatment of heart failure with beta-blocking agents.
  • Examination of the pathophysiology of heart failure, focusing on adrenergic tone.

Main Results:

  • Evidence indicates that high adrenergic tone is deleterious in patients with heart failure.
  • The detrimental effects associated with high adrenergic tone are partially reversible with beta-adrenergic blockade.
  • Beta-blocking agents represent a promising therapeutic avenue for heart failure treatment.

Conclusions:

  • Novel treatments for congestive heart failure are essential due to persistent high mortality.
  • Beta-adrenergic blockade shows potential in reversing harmful effects of elevated adrenergic tone in heart failure.
  • Further research and clinical application of beta-blocking agents are warranted for improved heart failure management.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and vasodilation. This widens airways and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.